Compare Abeona Therapeutics Inc (ABEO) vs SPDR Gold Trust (GLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SPDR Gold Trust — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while SPDR Gold Trust trades at $373. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| ABEO | GLD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $495.90 |
52-Week Low | $4.17 | $300.96 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GLD trades at $382.13, up 1.06% with a bearish technical signal from moving averages. Recent news highlights central bank gold purchases and analyst price targets near $4,600 per ounce for physical gold. The fund shows strong annual returns of 22.27% but faces resistance near $383-$387 levels amid mixed oscillators.
Outlook remains cautiously optimistic with institutional demand supporting prices, though technical resistance and Fed policy uncertainty pose near-term risks. Long-term bullion fundamentals appear intact, but volatility may persist around key economic data releases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
